GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SAGIMET BIOSCIENCES INC

Financial Performance:

• Raised $175 million in April 2024 to fund operations through 2028.
• Secured an additional $115 million via a reverse inquiry in late 2024.
• Current capitalization is sufficient to fund the second oral inhibitor program and initiate the topical inhibitor's human development.
• No specific quarterly revenue, profit margins, or debt figures were disclosed, reflecting the company's pre-commercial clinical stage.

Guidance and Future Outlook:

• U.S. Phase 3 trial for lead asset Denvafax (Denny) is expected to reach the primary endpoint by the end of 2026.
• Phase 2 data for the second oral inhibitor (more potent derivative) is anticipated around the same timeframe (late 2026).
• Human testing for the topical inhibitor is scheduled to begin in 2028.
• Long-term goal is to establish the molecule as the standard of care, replacing antibiotics and reducing reliance on topicals for moderate-to-severe acne.

Business Segments and Product Lines:

• Strategic pivot in April 2024 to focus exclusively on dermatology programs, specifically acne.
• Lead Asset (Denvafax/Fast Inhibitor): Targets Fatty Acid Synthase; inhibits sebum production and inflammation.
• Clinical Data: Partner data (Ascletus, China) showed ~20% improvement in IGA scores and 20% lesion reduction at 12 weeks; 52-week extension showed lesion reductions up to 80% for inflammatory lesions.
• New Asset: A second, more potent oral fast inhibitor currently in development.
• Pipeline: Topical fast inhibitor currently in formulation development for mild acne.
• Target Population: U.S. Phase 3 includes 800 patients (450 adolescents, 350 adults), with 530 entering the open-label extension.

Market and Competitive Landscape:

• Market Size: ~50 million U.S. patients with acne; ~10–15 million with moderate-to-severe acne requiring treatment.
• Unmet Need: Current treatments (antibiotics, topicals) have limitations regarding resistance, compliance, and side effects (e.g., photosensitivity, gut microbiome impact).
• Differentiation: Denvafax offers a specific mechanism of action (enzyme inhibition) vs. complex multi-pathway drugs like Accutane or anti-androgens.
• Adoption Strategy: Management predicts the drug will replace oral antibiotics and significantly reduce topical usage due to superior efficacy and ease of application (oral vs. caregiver-dependent topicals for truncal acne).

Risks and Challenges:

• Adolescent Compliance: Management addresses concerns regarding compliance in younger patients, citing a history of low non-compliance (<1-2%) in similar trials and the use of "smart caps" for real-time monitoring.
• Regulatory Uncertainty: Final labeling efficacy claims will depend on FDA review of the 12-week double-blind data, though long-term safety data from the open-label extension will be included.
• Clinical Execution: Risk of patient dropout in the long-term open-label extension (estimated ~20% loss based on partner data) and potential delays in site activation.

Management Commentary and Tone:

• Tone is highly confident and enthusiastic regarding the market opportunity and data alignment.
• Management emphasized FDA favorability, noting the agency's encouragement to include adolescent patients due to the molecule's well-characterized safety profile.
• Clear strategic direction expressed with a focus on displacing antibiotic therapy and establishing Denvafax as a step-up alternative to Accutane.

Analyst Questions and Answers:

• Q: Mechanism Differentiation: Management explained Fatty Acid Synthase inhibition targets sebum and inflammation directly, unlike the broader systemic effects of anti-androgens or antibiotics.
• Q: Timeline and Enrollment: First patient dosed October 21; enrollment expected to take six months; primary endpoint results expected by end of 2026.
• Q: Adolescent Inclusion: FDA suggested including 12–17-year-olds; 450 of the 800 patients will be adolescents (300 on drug, 150 on placebo in a 2:1 ratio).
• Q: Safety Profile: Long-term data showed only mild to moderate dry skin and dry eye; no serious adverse events (SAEs) or Grade 3 events reported.
• Q: Label Differentiation: Primary efficacy claims derived from the 12-week placebo-controlled period; long-term safety and efficacy data from the extension will support label expansion.

Other Key Points:

• The FDA recognized the pathology of acne is agnostic to demographic or ethnic background, supporting the use of Chinese clinical data for U.S. approval considerations.
• Smart cap technology will be utilized in both the controlled trial and open-label extension to ensure adherence and provide real-time feedback to sites and parents.
• Management indicated the second oral inhibitor may offer similar efficacy with potentially improved safety, or higher efficacy with comparable safety, pending 2026 data.
• Exploration of oily skin treatment with the topical formulation was mentioned as a potential future aesthetic indication.